DE69811710D1 - Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung - Google Patents

Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung

Info

Publication number
DE69811710D1
DE69811710D1 DE69811710T DE69811710T DE69811710D1 DE 69811710 D1 DE69811710 D1 DE 69811710D1 DE 69811710 T DE69811710 T DE 69811710T DE 69811710 T DE69811710 T DE 69811710T DE 69811710 D1 DE69811710 D1 DE 69811710D1
Authority
DE
Germany
Prior art keywords
formulas
delayed release
igf
producing igf
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69811710T
Other languages
English (en)
Other versions
DE69811710T2 (de
Inventor
Bret Shirley
Maninder Hora
Derek O'hagan
Manmohan Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DE69811710D1 publication Critical patent/DE69811710D1/de
Publication of DE69811710T2 publication Critical patent/DE69811710T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69811710T 1997-11-07 1998-11-06 Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung Expired - Fee Related DE69811710T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6489197P 1997-11-07 1997-11-07
US64891P 1997-11-07
US9606698P 1998-08-11 1998-08-11
US96066P 1998-08-11
PCT/US1998/023627 WO1999024061A1 (en) 1997-11-07 1998-11-06 Method for producing igf-1 sustained-release formulations

Publications (2)

Publication Number Publication Date
DE69811710D1 true DE69811710D1 (de) 2003-04-10
DE69811710T2 DE69811710T2 (de) 2004-03-25

Family

ID=26745003

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69811710T Expired - Fee Related DE69811710T2 (de) 1997-11-07 1998-11-06 Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung

Country Status (7)

Country Link
US (1) US6573238B2 (de)
EP (1) EP1028746B1 (de)
JP (1) JP2001522812A (de)
AT (1) ATE233097T1 (de)
AU (1) AU1384199A (de)
DE (1) DE69811710T2 (de)
WO (1) WO1999024061A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112341B1 (en) 1999-04-13 2006-09-26 Nektar Therapeutics Pulmonary administration of dry powder formulations for treating infertility
US6303138B1 (en) 1999-09-17 2001-10-16 Depuy Orthopaedics Endothelin-based compositions for enhancing connective tissue repair
AU2275700A (en) * 2000-02-09 2001-08-20 White Spot Ag Sustained release composition comprising insuline like growth factor
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
ES2292634T3 (es) † 2000-12-21 2008-03-16 Alrise Biosystems Gmbh Procedimiento de transicion de fase inducida para la produccion de microparticulas que contienen agentes hidrofilos activos.
JP2005509611A (ja) * 2001-10-10 2005-04-14 ピエール、ファーブル、メディカマン 徐放型生物分解性微小球およびその製造方法
NZ535008A (en) * 2002-02-08 2005-09-30 Alkermes Inc Polymer-based compositions for sustained release
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004060387A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004108115A1 (ja) 2003-06-03 2004-12-16 Santen Pharmaceutical Co., Ltd. 微粒子の製造法
US20050175709A1 (en) * 2003-12-11 2005-08-11 Baty Ace M.Iii Therapeutic microparticles
CA2578951A1 (en) * 2004-08-30 2006-03-09 Theregen, Inc. Cultured three dimensional tissues and uses thereof
MX2009012856A (es) * 2007-06-06 2009-12-15 Debio Rech Pharma Sa Composicion farmaceutica de liberacion lenta hecha de microparticulas.
US20090022805A1 (en) * 2007-06-28 2009-01-22 Joram Slager Polypeptide microparticles having sustained release characteristics, methods and uses
US7910123B2 (en) 2007-09-05 2011-03-22 Warsaw Orthopedic Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent
NZ583632A (en) 2007-11-16 2012-05-25 Univ Rockefeller Antibodies specific for the protofibril form of beta-amyloid protein
GB0814302D0 (en) * 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
CN103068371A (zh) * 2010-03-29 2013-04-24 赢创有限公司 用于在局部给药位点改进药物组合物的滞留的组合物和方法
US8865220B2 (en) * 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
US10519434B2 (en) 2012-07-13 2019-12-31 Diomics Corporation Biologic sample collection devices and methods of production and use thereof
WO2016025021A1 (en) * 2014-08-15 2016-02-18 Diomics Corporation Films for biologic analyte collection and analysis and methods of production and use thereof
CA3013904C (en) 2016-02-10 2023-12-12 Rutgers, The State University Of New Jersey Novel anti-lam and anti-pim6/lam monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
EP3738621A4 (de) * 2018-01-10 2021-10-13 G2Gbio, Inc. Kollagenpeptidhaltiger polycaprolactonmikrokugelfüllstoff und herstellungsverfahren dafür
WO2021167957A1 (en) * 2020-02-20 2021-08-26 Dianomi Therapeutics, Inc. Inorganic coatings for the sustained release of bioactive compounds
WO2022159658A1 (en) * 2021-01-22 2022-07-28 University Of Connecticut Synthetic artificial stem cells (sasc)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4542025A (en) 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
CH679207A5 (de) 1989-07-28 1992-01-15 Debiopharm Sa
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
DK0674506T3 (da) 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
AU8017494A (en) 1993-10-22 1995-05-08 Genentech Inc. Method for preparing microspheres comprising a fluidized bed drying step
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
JP2001522813A (ja) 1997-11-07 2001-11-20 カイロン コーポレイション 新規のｉｇｆ−ｉ組成物およびその使用

Also Published As

Publication number Publication date
JP2001522812A (ja) 2001-11-20
AU1384199A (en) 1999-05-31
ATE233097T1 (de) 2003-03-15
WO1999024061A1 (en) 1999-05-20
US6573238B2 (en) 2003-06-03
EP1028746B1 (de) 2003-02-26
DE69811710T2 (de) 2004-03-25
EP1028746A1 (de) 2000-08-23
US20020013273A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
DE69811710D1 (de) Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
DE69632684D1 (de) Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
DE69706537D1 (de) Verfahren zur herstellung von hohlen kieselsäureteilchen
DE69110475D1 (de) Verfahren zur herstellung von perfluorolefinen.
DE68907320D1 (de) Verfahren zur herstellung von modifizierten polypropylen-zusammensetzungen.
DE69331460D1 (de) Ein verbessertes verfahren zur herstellung von wachsfreien kaugummis mit kurzen härtungszeiten
DE69715070T2 (de) Verfahren zur Herstellung von Quantum-Teilungsphosphoren
DE69122753D1 (de) Ein verbessertes verfahren zur herstellung von substituierten indolone derivaten
DE58902137D1 (de) Verfahren zur herstellung von caprolacton.
DE69926059D1 (de) Verfahren zur herstellung von replikas unter bewahrung des originals
DE69712779D1 (de) Verfahren zur herstellung von kunststeinen
ATE274511T1 (de) Verfahren zur herstellung von eprosartan
DE69827240D1 (de) Verfahren zur herstellung von eprosartan
DE69719042T2 (de) Verfahren zur herstellung von epsilon-caprolactam
DE69809373D1 (de) Verfahren zur herstellung von siliconlatexen
DE59002735D1 (de) Verfahren zur herstellung von implantaten.
ATE198022T1 (de) Verfahren zur herstellung von aspartampulver
DE68905346D1 (de) 3-(2-hydroperoxy-2-propyl)phenol und verfahren zur herstellung von resorcin mit diesem phenol.
ATE216873T1 (de) Verfahren zur herstellung von schweisshemmenden pulvern
ATE225797T1 (de) Verfahren zur herstellung von oxazaphosphorin-2- aminen
DE59007460D1 (de) Verfahren zur herstellung von n-alkyl-halogenanilinen.
DE59808308D1 (de) Verfahren zur herstellung von tassen
ATE237607T1 (de) Verfahren zur herstellung von 3-ispchromanon
DE59802548D1 (de) Verfahren zur herstellung von webware
DE59811807D1 (de) Verfahren zur herstellung von chlorbenzoxazolen

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee